IDH1-mutated relapsed or refractory AML: current challenges and future prospects

IDH1-mutated relapsed or refractory AML: current challenges and future prospects

Juan Eduardo Megías-Vericat,1 Octavio Ballesta-López,1 Eva Barragán,2,3 Pau Montesinos2,31Servicio de Farmacia, Área del Medicamento, Hospital Universitari i Politècnic La Fe, Valencia, Spain; 2Servicio de Hematología y Hemoterapia, H...

Full description

Bibliographic Details
Main Authors: Megías-Vericat JE, Ballesta-López O, Barragán E, Montesinos P
Format: Article
Language:English
Published: Dove Medical Press 2019-06-01
Series:Blood and Lymphatic Cancer: Targets and Therapy
Subjects:
IDH1
isocitrate dehydrogenase 1
acute myeloid leukemia
relapsed/refractory
ivosidenib
FT-2102
venetoclax.
Online Access:https://www.dovepress.com/idh1-mutated-relapsed-or-refractory-aml-current-challenges-and-future--peer-reviewed-article-BLCTT

Internet

https://www.dovepress.com/idh1-mutated-relapsed-or-refractory-aml-current-challenges-and-future--peer-reviewed-article-BLCTT

Similar Items